An observational study in Coma; Prolonged and Amantadine, sponsored by Dokuz Eylul University. Status unknown at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-09-06.
Sponsored by Dokuz Eylul University · Observational
The study was a single center observational-prospective study and approved by local ethics committee. Patients in coma state due to traumatic brain injury, cardiac arrest or ischemic stroke who are older than 18 years of age were included in the study. Patients who received amantadine 200mg/day for fourteen days according to ICU protocols decided by primary physician formed the amantadine group, and the rest of the subjects were included in the control group. All patients were evaluated for Glasgow Coma Score, JFK Coma Recovery Scale and Disability Rating Scale once a week for three months.
Patients with the coma state duo to ischemic stroke, brain hemorhage, anoxic brain damage included in this study.
Exclusion Criteria:
Patients admitted to the critical care with diagnosis of coma state who have received amantadin 200 mg / day for fourteen days according to İCU protocols decided by primary physician
Drug: amantadine sulphate
Patients admitted to the critical care with diagnosis of coma state who haven't received amantadin
Change in Glascow Coma Score
Glascow Coma Score
Time frame: 1. At the time of enrollment 2. 12 weeks after the enrollment
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dokuz Eylul University